Summary
Among the key developments addressed in the new 750-page November 2006 edition:
Neurodegenerative Disorders
- What are the leading Alzheimer's and Parkinson's disease brands?
- What disease-modifying agents are emerging?
- How are companies managing the patent exposure within their neurodegenerative portfolios?
Multiple Sclerosis
- How is Tysabri (Elan) performing following its temporary suspension?
- What is the latest clinical data on Mylinax (Serono/IVAX) and Neurelan (Elan/Acorda)?
- What other products are in the pipeline?
Attention Deficit Hyperactivity Disorder (ADHD)
- What products are in Phase II/III and when will they reach the market?
- How is the launch of Shire's MethyPatch going?
- To what degree will the approval of NRP104 (Shire/New River) change the market dynamics?
Depression
- What impact have generics had on market dynamics?
- How have safety concerns influenced prescribing habits?
- What Phase IV data has driven sales?
Sleep Disorders
- Will Neurocrine's indiplon reach the market?
- How does gaboxadol (Merck & Co/ Lundbeck) compare to its peers?
- What is sanofi-aventis' pipeline looking like?
Schizophrenia - new in this edition!
- How has the safety of atypical antipsychotics affected the market?
- Who is the market leader and why?
- What pipeline products are in development and how do they compare with the competition?
For each therapy area the report provides
Comprehensive Overview
- Patient statistics:
- Prevalence, diagnosed and treatment rates
- Patient populations in the US, Europe and Japan
Growth drivers:
Risk factors (genetics, age, sex), medical guidelines, unmet clinical need and off-label use in other CNS disorders
Growth dampeners:
Safety issues, label changes, impact of generics, reimbursement and ethical issues
An overview of the value of the CNS market:
- Global sales
- Sales growth to 2012
A review of the major players based on market share/sales
Current treatments:
- Competitor analysis of leading brands and companies
- Patent exposure
- Where and why there is still an unmet clinical need?
- Sales forecasts by product 2005-2012
Drugs in Phase II/III development:
- Focus on new classes of drugs and companies involved
- Sales forecasts by product year of launch to 2012
Competitor ratio analysis:
Analysis of drugs and companies within each sector based on drugs analysed in the report and using 5 point criteria for success evaluation
Winners & losers:
Identify the winners and losers within each sector based on competitor analysis, current pipeline products and market conditions
About the Author
Dr Cheryl Barton is a highly regarded independent consultant with over 15 years research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer's disease to schizophrenia, Dr Barton joined Dutch investment bank ABN Amro NV as a senior equity analyst. At ABN Amro NV she was lead analyst on major pharmaceutical companies such as Roche and Sanofi-Synthlabo, and assessed the potential impact of new drug development on European Stocks.
In 2002, Dr Barton established a consulting business to provide independent, tailor-made, pharmaceutical thematic research to investment houses and pharmaceutical companies. The research combines independent scientific analysis with patient-based models to forecast the potential sales growth of key drugs in clinical development.
CNS Drug Discoveries:
- what the future holds
- Understand the prospects for this US$67.8 billion market.
- Revised edition provides critical development update.
- Unique market share and sales forecasts by product to 2012.
- A comprehensive examination of 6 major CNS therapy areas.
- Detailed competitor analysis of current and upcoming products.
|
